N/A
Manufactured by Aurobindo Pharma Limited
47 FDA adverse event reports analyzed
Last updated: 2026-04-15
LIDOCAINE HCI is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Aurobindo Pharma Limited. The most commonly reported adverse reactions for LIDOCAINE HCI include ABDOMINAL DISTENSION, ASTHENIA, DIARRHOEA, FATIGUE, NAUSEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for LIDOCAINE HCI.
Out of 9 classified reports for LIDOCAINE HCI:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 47 FDA FAERS reports that mention LIDOCAINE HCI. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include ABDOMINAL DISTENSION, ASTHENIA, DIARRHOEA, FATIGUE, NAUSEA, ABDOMINAL PAIN. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Aurobindo Pharma Limited in connection with LIDOCAINE HCI. Always verify the specific product and NDC with your pharmacist.